Why Lasmiditan?

Lasmiditan is a member of a novel chemical class called "ditans".

Lasmiditan penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway.

Learn More About Lasmiditan

Lasmiditan does not interact with vasoconstrictor 5-HT1B/1D receptors activated by triptans.

No evidence of drug-related cardiovascular adverse effects or chest symptoms in the previous six clinical studies.

Learn More About Lasmiditan

Six clinical studies provide proof of concept in the treatment of acute migraine attacks.

Reduced moderate or severe headache at baseline to mild or none 2 hours after dosing (p<0.0001) in 391 patients.

Differentiation of individual doses from placebo seen as early as 30 minutes after dosing.

Learn More About Lasmiditan

Development Plan

Lasmiditan completes Phase 2b proof of concept trial

Having received definitive proof of concept of lasmiditan treating acute migraine in Phase 2b trials, CoLucid is designing pivotal trials to further confirm lasmiditan's safety and efficacy prior to submission for approval.

View Our Development Plan

Meet CoLucid

Linda Hogan

Vice President of Business Development

Linda Hogan, MBA, CLP

Linda has over 25 years of experience in the healthcare industry, having served as Vice President of Global Business Development for Aventis in…

Read More Meet The Others

About Migraines

Partners

A migraine is a painful neurological condition, of which the most common symptom is an intense and disabling headache.

Learn More About Migraines
Partners